Antihyperkinesis/ADHD Changes in New PDL

Effective November 1, 2017, the N.C. Division of Medical Assistance (DMA) implemented approved changes to the Antihyperkinesis/ADHD drug class on the N.C. Medicaid and N.C. Health Choice Preferred Drug List (PDL). Providers are encouraged to review this important information.

Behavioral Health (Antihyperkinesis/ADHD)

• Metadate CD capsules have been removed from the PDL as they are discontinued
• Clonidine ER tablet (generic for Kapvay), Desoxyn Tablet (methamphetamine HCl), dextroamphetamine ER capsule (generic for Dexedrine Spansules), all methylphenidate ER tablets, and Ritalin LA Capsule (methylphenidate 20 mg, 30 mg, 40 mg, 60 mg) moved from preferred to non-preferred.
• Quillichew ER Oral (methylphenidate), Vyvanse Chewable Tablets and Aptenzio XR moved from non-preferred to preferred

Currently there are manufacturer shortages of Kapvay and Derma-Smoothe body and scalp oil. DMA has authorized 30 day approvals for the generic non-preferred medications.

Note: All non-preferred medications require a prior approval. The recommended methods of submission for pharmacy prior approval requests are via fax (855-710-1969) or the secure provider portal.

For additional information on the recent PDL changes, refer to the November 2017 Medicaid Bulletin.